Related Experiment Video
Updated: Jan 1, 2026
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
The use of apatinib in treating primary pleural synovial sarcoma: A case report
Sumei Chen1, Ke Zhang1, Xianqin Wan1
1Department of Radiation Oncology, Hangzhou Cancer Hospital.
Rationale:
Apatinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. It has been shown that apatinib is effective and safe for treatment of multiple solid tumors, including gastric cancer, liver cancer, non-small-cell lung cancer, and breast cancer. However, there is currently no consensus as to using Apatinib for the treatment of pleural synovial sarcoma, due to the rarity of primary pleural synovial sarcoma and lack of clinical studies as a consequence.
Patient Concerns And Diagnoses:
We reported here in the case of a 26-year-old Chinese woman diagnosed with pleural synovial sarcoma. She has undergone 2 surgeries, multiple regimens of chemotherapy and traditional Chinese medicine in other hospitals. Then the patient was admitted to our hospital with the compliant of chest pain and dyspnea. The medical history and available data supported the diagnosis of recurrence of pleural synovial sarcoma.
Interventions And Outcomes:
Due to the lack of efficacy of previous standard treatment, the patient was given apatinib and radiotherapy to relieve the symptoms. This patient achieved stable disease with apatinib at a dose of 500 mg/day. Her progression-free survival time was more than 7 months, and her overall survival was 8.5 months. Except for hand-foot syndrome, no grade 3 or 4 side effects were observed.
Conclusions:
Apatinib may thus be an option for treatment of advanced synovial sarcoma after failure of other treatments. However, further study is needed to determine the efficacy of apatinib in pleural synovial sarcoma.
Insights
Apatinib, an oral tyrosine kinase inhibitor, shows promise for treating advanced pleural synovial sarcoma. This case study demonstrates its potential efficacy and safety in a patient who failed other treatments, warranting further investigation.
Area of Science:
- Oncology
- Medical Research
- Clinical Case Study
Background:
- Apatinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
- Apatinib has demonstrated efficacy in various solid tumors, but its use in pleural synovial sarcoma is not established.
- Pleural synovial sarcoma is a rare condition, limiting clinical studies and consensus on treatment.
Observation:
- A 26-year-old woman with recurrent pleural synovial sarcoma presented with chest pain and dyspnea.
- The patient had previously undergone surgery, chemotherapy, and traditional Chinese medicine without success.
- Diagnosis of recurrent pleural synovial sarcoma was confirmed by medical history and available data.
Findings:
- Apatinib (500 mg/day) combined with radiotherapy resulted in stable disease.
- The patient achieved a progression-free survival of over 7 months and an overall survival of 8.5 months.
- The primary side effect observed was hand-foot syndrome; no grade 3 or 4 adverse events occurred.
Implications:
- Apatinib may be a viable treatment option for advanced synovial sarcoma refractory to standard therapies.
- Further clinical studies are necessary to validate the efficacy of apatinib specifically for pleural synovial sarcoma.
- This case highlights the potential of targeted therapies in rare sarcoma subtypes.
Related Concept Videos
02:56Treatment Resistant Cancers
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...